14 January 2026 - The CDER and CBER have collaborated with the EMA to develop 10 guiding principles that industry and product developers can consider when using artificial intelligence to advance drug and biological product development.

To fully realise the potential of AI while ensuring reliability of the information to ensure patient safety and regulatory excellence, it is essential to establish guiding principles that address the unique challenges and considerations of AI applications in drug development.

Read FDA News